#BEGIN_DRUGCARD DB03608

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Azidin
Berenil
Ganasag
Pirocide

# CAS_Registry_Number:
536-71-0

# ChEBI_ID:
Not Available

# Chemical_Formula:
C14H15N7

# Chemical_IUPAC_Name:
4-[(2E)-3-(4-carbamimidoylphenyl)triaz-2-en-1-yl]benzene-1-carboximidamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
An effective trypanocidal agent.

# Dosage_Forms:
Not Available

# Drug_Category:
Trypanocidal Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Diminazene

# HET_ID:
BRN

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C14H15N7/c15-13(16)9-1-5-11(6-2-9)19-21-20-12-7-3-10(4-8-12)14(17)18/h1-8H,(H3,15,16)(H3,17,18)(H,19,20)

# InChI_Key:
InChIKey=XNYZHCFCZNMTFY-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3608

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
281.3158

# Molecular_Weight_Mono:
281.138893515

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1HD2

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.09

# Predicted_LogS:
-3.4

# Predicted_Water_Solubility:
1.02e-01 g/l

# Primary_Accession_No:
DB03608

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
2354

# PubChem_Substance_ID:
46504758

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00754

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(=N)C1=CC=C(N\N=N\C2=CC=C(C=C2)C(N)=N)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
1,3-TRIS-(4'AMIDINOPHENYL)TRIAZINE
4,4'-(1-Triazene-1,3-diyl)bis-benzenecarboximidamide
4,4'-(Diazoamino)benzamidine
Diminazene aceturate
Diminazine
Diminazine aceturate

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:26 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Diminazene

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Mitochondrion. Cytoplasm. Peroxisome

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PRDX5

# Drug_Target_1_GenBank_ID_Gene:
AJ249483

# Drug_Target_1_GenBank_ID_Protein:
6523289

# Drug_Target_1_GeneCard_ID:
PRDX5

# Drug_Target_1_Gene_Name:
PRDX5

# Drug_Target_1_Gene_Sequence:
>645 bp
ATGGGACTAGCTGGCGTGTGCGCCCTGAGACGCTCAGCGGGCTATATACTCGTCGGTGGG
GCCGGCGGTCAGTCTGCGGCAGCGGCAGCAAGACGGTGCAGTGAAGGAGAGTGGGCGTCT
GGCGGGGTCCGCAGTTTCAGCAGAGCCGCTGCAGCCATGGCCCCAATCAAGGTGGGAGAT
GCCATCCCAGCAGTGGAGGTGTTTGAAGGGGAGCCAGGGAACAAGGTGAACCTGGCAGAG
CTGTTCAAGGGCAAGAAGGGTGTGCTGTTTGGAGTTCCTGGGGCCTTCACCCCTGGATGT
TCCAAGACACACCTGCCAGGGTTTGTGGAGCAGGCTGAGGCTCTGAAGGCCAAGGGAGTC
CAGGTGGTGGCCTGTCTGAGTGTTAATGATGCCTTTGTGACTGGCGAGTGGGGCCGAGCC
ACAAAGGCGGAAGGCAAGGTTCGGCTCCTGGCTGATCCCACTGGGGCCTTTGGGAAGGAG
ACAGACTTATTACTAGATGATTCGCTGGTGTCCATCTTTGGGAATCGACGTCTCAAGAGG
TTCTCCATGGTGGTACAGGATGGCATAGTGAAGGCCCTGAATGTGGAACCAGATGGCACA
GGCCTCACCTGCAGCCTGGCACCCAATATCATCTCACAGCTCTGA

# Drug_Target_1_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_1_General_References:
10095767	Kropotov A, Sedova V, Ivanov V, Sazeeva N, Tomilin A, Krutilina R, Oei SL, Griesenbeck J, Buchlow G, Tomilin N: A novel human DNA-binding protein with sequence similarity to a subfamily of redox proteins which is able to repress RNA-polymerase-III-driven transcription of the Alu-family retroposons in vitro. Eur J Biochem. 1999 Mar;260(2):336-46.
10514471	Yamashita H, Avraham S, Jiang S, London R, Van Veldhoven PP, Subramani S, Rogers RA, Avraham H: Characterization of human and murine PMP20 peroxisomal proteins that exhibit antioxidant activity in vitro. J Biol Chem. 1999 Oct 15;274(42):29897-904.
10521424	Knoops B, Clippe A, Bogard C, Arsalane K, Wattiez R, Hermans C, Duconseille E, Falmagne P, Bernard A: Cloning and characterization of AOEB166, a novel mammalian antioxidant enzyme of the peroxiredoxin family. J Biol Chem. 1999 Oct 22;274(43):30451-8.
10679306	Zhou Y, Kok KH, Chun AC, Wong CM, Wu HW, Lin MC, Fung PC, Kung H, Jin DY: Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits p53-induced apoptosis. Biochem Biophys Res Commun. 2000 Feb 24;268(3):921-7.
10751410	Seo MS, Kang SW, Kim K, Baines IC, Lee TH, Rhee SG: Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J Biol Chem. 2000 Jul 7;275(27):20346-54.
10931946	Hu RM, Han ZG, Song HD, Peng YD, Huang QH, Ren SX, Gu YJ, Huang CH, Li YB, Jiang CL, Fu G, Zhang QH, Gu BW, Dai M, Mao YF, Gao GF, Rong R, Ye M, Zhou J, Xu SH, Gu J, Shi JX, Jin WR, Zhang CK, Wu TM, Huang GY, Chen Z, Chen MD, Chen JL: Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9543-8.
11518528	Declercq JP, Evrard C, Clippe A, Stricht DV, Bernard A, Knoops B: Crystal structure of human peroxiredoxin 5, a novel type of mammalian peroxiredoxin at 1.5 A resolution. J Mol Biol. 2001 Aug 24;311(4):751-9.
1286669	Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis. 1992 Dec;13(12):992-1001.

# Drug_Target_1_HGNC_ID:
HGNC:9355

# Drug_Target_1_HPRD_ID:
05958

# Drug_Target_1_ID:
1119

# Drug_Target_1_Locus:
11q13

# Drug_Target_1_Molecular_Weight:
22027

# Drug_Target_1_Name:
Peroxiredoxin-5, mitochondrial

# Drug_Target_1_Number_of_Residues:
214

# Drug_Target_1_PDB_ID:
1OC3

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF08534	Redoxin

# Drug_Target_1_Protein_Sequence:
>Peroxiredoxin-5, mitochondrial precursor
MGLAGVCALRRSAGYILVGGAGGQSAAAAARRCSEGEWASGGVRSFSRAAAAMAPIKVGD
AIPAVEVFEGEPGNKVNLAELFKGKKGVLFGVPGAFTPGCSKTHLPGFVEQAEALKAKGV
QVVACLSVNDAFVTGEWGRAHKAEGKVRLLADPTGAFGKETDLLLDDSLVSIFGNRRLKR
FSMVVQDGIVKALNVEPDGTGLTCSLAPNIISQL

# Drug_Target_1_Reaction:
2 R'-SH + ROOH = R'-S-S-R' + H2O + ROH

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Reduces hydrogen peroxide and alkyl hydroperoxides with reducing equivalents provided through the thioredoxin system. Involved in intracellular redox signaling

# Drug_Target_1_SwissProt_ID:
P30044

# Drug_Target_1_SwissProt_Name:
PRDX5_HUMAN

# Drug_Target_1_Synonyms:
AOEB166
Alu corepressor 1
Antioxidant enzyme B166
EC 1.11.1.15
Liver tissue 2D-page spot 71B
PLP
Peroxiredoxin-5, mitochondrial precursor
Peroxisomal antioxidant enzyme
Prx-V
TPx type VI
Thioredoxin peroxidase PMP20
Thioredoxin reductase

# Drug_Target_1_Theoretical_pI:
8.77

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X56628

# Drug_Target_2_GenBank_ID_Protein:
46660

# Drug_Target_2_GeneCard_ID:
qacR

# Drug_Target_2_Gene_Name:
qacR

# Drug_Target_2_Gene_Sequence:
>1545 bp
CTGATTTCATTTTTTACAAAAACTACTGATATGATGACATCAAAAAAAAGATGGACTGCA
CTAGTAGTATTAGCTGTTAGTTTGTTTGTTGTTACAATGGATATGACAATATTAATTATG
GCTTTACCGGAATTAGTAAGAGAGTTAGAGCCTTCTGGTACCCAACAGTTATGGATAGTT
GATATATACTCTCTTGTTTTAGCTGGCTTTATAATTCCATTGAGTGCCTTTGCTGATAAA
TGGGGAAGAAAAAAAGCATTATTAACTGGATTTGCTTTATTTGGCCTCGTTTCATTAGCT
ATATTTTTCGCAGAAAGTGCAGAGTTCGTAATAGCTATTCGATTTTTACTTGGTATTGCA
GGTGCTTTAATAATGCCAACTACCCTTTCAATGATAAGAGTAATTTTTGAAAACCCTAAA
GAAAGGGCCACTGCATTAGCTGTATGGTCAATCGCTTCATCGATAGGTGCTGTTTTTGGA
CCAATTATCGGAGGAGCTTTACTTGAGCAATTTTCATGGCACTCGGCATTTTTAATTAAT
GTACCGTTTGCGATAATAGCAGTTGTAGCAGGTTTATTTTTATTACCAGAGTCTAAGTTA
TCAAAAGAAAAGTCTCACTCGTGGGATATTCCTTCTACAATTTTATCAATTGCAGGCATG
ATTGGACTGGTATGGAGTATCAAAGAATTTTCAAAAGAAGGACTAGCAGATATTATTCCA
TGGGTTGTAATAGTATTAGCAATTACCATGATAGTGATATTTGTTAAACGTAATTTATCA
AGTTCTGATCCAATGTTAGACGTAAGACTTTTTAAAAAGAGATCATTTTCAGCTGGTACA
ATTGCTGCATTTATGACAATGTTTGCAATGGCATCTGTTTTGTTATTAGCTTCACAATGG
TTACAGGTTGTGGAAGAACTTTCTCCTTTTAAAGCTGGCTTATACCTATTACCTATGGCA
ATAGGAGATATGGTGTTTGCACCAATTGCACCCGGATTAGCGGCGCGATTTGGACCGAAA
ATAGTGTTACCTTCCGGAATTGGAATTGCAGCCATTGGCATGTTTATTATGTATTTCTTT
GGTCATCCATTATCATATTCTACAATGGCTTTAGCATTAATTTTAGTTGGAGCTGGTATG
GCTTCACTAGCAGTTGCATCTGCTCTAATAATGTTAGAAACACCTACATCAAAAGCAGGT
AATGCAGCTGCTGTTGAAGAGTCTATGTATGACCTTGGAAATGTTTTTGGTGTAGCAGTA
CTTGGTAGCCTATCTTCTATGCTTTATCGTGTATTTTTAGATATTTCATCTTTTTCATCA
AAAGGTATAGTTGGAGATTTAGCTCATGTAGCTGAAGAATCTGTAGTGGGCGCTGTCGAA
GTAGCTAAAGCTACGGGGATAAAACAGCTTGCAAACGAGGCTGTAACATCATTTAATGAT
GCTTTTGTAGCAACTGCTTTAGTAGGTGGGATTATCATGATTATCATTTCAATAGTTGTC
TATTTGTTAATTCCCAAATCACTTGATATAACTAAACAAAAATAG

# Drug_Target_2_General_Function:
Transcription

# Drug_Target_2_General_References:
11717268	Grkovic S, Brown MH, Schumacher MA, Brennan RG, Skurray RA: The staphylococcal QacR multidrug regulator binds a correctly spaced operator as a pair of dimers. J Bacteriol. 2001 Dec;183(24):7102-9.
11739955	Schumacher MA, Miller MC, Grkovic S, Brown MH, Skurray RA, Brennan RG: Structural mechanisms of QacR induction and multidrug recognition. Science. 2001 Dec 7;294(5549):2158-63.
11867549	Schumacher MA, Miller MC, Grkovic S, Brown MH, Skurray RA, Brennan RG: Structural basis for cooperative DNA binding by two dimers of the multidrug-binding protein QacR. EMBO J. 2002 Mar 1;21(5):1210-8.
12648720	Schumacher MA, Brennan RG: Deciphering the molecular basis of multidrug recognition: crystal structures of the Staphylococcus aureus multidrug binding transcription regulator QacR. Res Microbiol. 2003 Mar;154(2):69-77.
2089219	Rouch DA, Cram DS, DiBerardino D, Littlejohn TG, Skurray RA: Efflux-mediated antiseptic resistance gene qacA from Staphylococcus aureus: common ancestry with tetracycline- and sugar-transport proteins. Mol Microbiol. 1990 Dec;4(12):2051-62.
9660841	Grkovic S, Brown MH, Roberts NJ, Paulsen IT, Skurray RA: QacR is a repressor protein that regulates expression of the Staphylococcus aureus multidrug efflux pump QacA. J Biol Chem. 1998 Jul 17;273(29):18665-73.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6461

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
22174.2

# Drug_Target_2_Name:
HTH-type transcriptional regulator qacR

# Drug_Target_2_Number_of_Residues:
188

# Drug_Target_2_PDB_ID:
1QVU

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00440	TetR_N
PF08360	TetR_C_5

# Drug_Target_2_Protein_Sequence:
>HTH-type transcriptional regulator qacR
MNLKDKILGVAKELFIKNGYNATTTGEIVKLSESSKGNLYYHFKTKENLFLEILNIEESK
WQEQWKKEQIKCKTNREKFYLYNELSLTTEYYYPLQNAIIEFYTEYYKTNSINEKMNKLE
NKYIDAYHVIFKEGNLNGEWCINDVNAVSKIAANAVNGIVTFTHEQNINERIKLMNKFSQ
IFLNGLSK

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Transcriptional repressor of qacA. Binds to IR1, an unusually long 28 bp operator, which is located downstream from the qacA promoter and overlaps its transcription start site. QacR is induced from its IR1 site by binding to one of many structurally dissimilar cationic lipophilic compounds, which are also substrates of qacA

# Drug_Target_2_SwissProt_ID:
P0A0N4

# Drug_Target_2_SwissProt_Name:
QACR_STAAU

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
8.55

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Secreted protein
extracellular space

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
PRSS1

# Drug_Target_3_GenBank_ID_Gene:
M22612

# Drug_Target_3_GenBank_ID_Protein:
521216

# Drug_Target_3_GeneCard_ID:
PRSS1

# Drug_Target_3_Gene_Name:
PRSS1

# Drug_Target_3_Gene_Sequence:
>744 bp
ATGAATCCACTCCTGATCCTTACCTTTGTGGCAGCTGCTCTTGCTGCCCCCTTTGATGAT
GATGACAAGATCGTTGGGGGCTACAACTGTGAGGAGAATTCTGTCCCCTACCAGGTGTCC
CTGAATTCTGGCTACCACTTCTGTGGTGGCTCCCTCATCAACGAACAGTGGGTGGTATCA
GCAGGCCACTGCTACAAGTCCCGCATCCAGGTGAGACTGGGAGAGCACAACATCGAAGTC
CTGGAGGGGAATGAGCAGTTCATCAATGCAGCCAAGATCATCCGCCACCCCCAATACGAC
AGGAAGACTCTGAACAATGACATCATGTTAATCAAGCTCTCCTCACGTGCAGTAATCAAC
GCCCGCGTGTCCACCATCTCTCTGCCCACCGCCCCTCCAGCCACTGGCACGAAGTGCCTC
ATCTCTGGCTGGGGCAACACTGCGAGCTCTGGCGCCGACTACCCAGACGAGCTGCAGTGC
CTGGATGCTCCTGTGCTGAGCCAGGCTAAGTGTGAAGCCTCCTACCCTGGAAAGATTACC
AGCAACATGTTCTGTGTGGGCTTCCTTGAGGGAGGCAAGGATTCATGTCAGGGTGATTCT
GGTGGCCCTGTGGTCTGCAATGGACAGCTCCAAGGAGTTGTCTCCTGGGGTGATGGCTGT
GCCCAGAAGAACAAGCCTGGAGTCTACACCAAGGTCTACAACTACGTGAAATGGATTAAG
AACACCATAGCTGCCAATAGCTAA

# Drug_Target_3_General_Function:
Involved in protease activity

# Drug_Target_3_General_References:
10204851	Ferec C, Raguenes O, Salomon R, Roche C, Bernard JP, Guillot M, Quere I, Faure C, Mercier B, Audrezet MP, Guillausseau PJ, Dupont C, Munnich A, Bignon JD, Le Bodic L: Mutations in the cationic trypsinogen gene and evidence for genetic heterogeneity in hereditary pancreatitis. J Med Genet. 1999 Mar;36(3):228-32.
10381903	Witt H, Luck W, Becker M: A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology. 1999 Jul;117(1):7-10.
10930381	Teich N, Ockenga J, Hoffmeister A, Manns M, Mossner J, Keim V: Chronic pancreatitis associated with an activation peptide mutation that facilitates trypsin activation. Gastroenterology. 2000 Aug;119(2):461-5.
11788572	Pfutzer R, Myers E, Applebaum-Shapiro S, Finch R, Ellis I, Neoptolemos J, Kant JA, Whitcomb DC: Novel cationic trypsinogen (PRSS1) N29T and R122C mutations cause autosomal dominant hereditary pancreatitis. Gut. 2002 Feb;50(2):271-2.
2598466	Kimland M, Russick C, Marks WH, Borgstrom A: Immunoreactive anionic and cationic trypsin in human serum. Clin Chim Acta. 1989 Sep 15;184(1):31-46.
3011602	Emi M, Nakamura Y, Ogawa M, Yamamoto T, Nishide T, Mori T, Matsubara K: Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene. 1986;41(2-3):305-10.
8683601	Gaboriaud C, Serre L, Guy-Crotte O, Forest E, Fontecilla-Camps JC: Crystal structure of human trypsin 1: unexpected phosphorylation of Tyr151. J Mol Biol. 1996 Jun 28;259(5):995-1010.
8841182	Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, Martin SP, Gates LK Jr, Amann ST, Toskes PP, Liddle R, McGrath K, Uomo G, Post JC, Ehrlich GD: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996 Oct;14(2):141-5.
9322498	Gorry MC, Gabbaizedeh D, Furey W, Gates LK Jr, Preston RA, Aston CE, Zhang Y, Ulrich C, Ehrlich GD, Whitcomb DC: Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology. 1997 Oct;113(4):1063-8.
9633818	Teich N, Mossner J, Keim V: Mutations of the cationic trypsinogen in hereditary pancreatitis. Hum Mutat. 1998;12(1):39-43.

# Drug_Target_3_HGNC_ID:
HGNC:9475

# Drug_Target_3_HPRD_ID:
02039

# Drug_Target_3_ID:
3176

# Drug_Target_3_Locus:
7q32-qter|7q34

# Drug_Target_3_Molecular_Weight:
26558

# Drug_Target_3_Name:
Trypsin-1

# Drug_Target_3_Number_of_Residues:
247

# Drug_Target_3_PDB_ID:
1TRN

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_3_Protein_Sequence:
>Trypsin-1 precursor
MNPLLILTFVAAALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSLINEQWVVS
AGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVIN
ARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKIT
SNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIK
NTIAANS

# Drug_Target_3_Reaction:
Preferential cleavage: Arg!, Lys! INHIBITOR Tos-Lys-CH2Cl; Tos-Arg-CH2Cl

# Drug_Target_3_Signals:
1-15

# Drug_Target_3_Specific_Function:
Preferential cleavage:Arg-|-Xaa, Lys-|-Xaa

# Drug_Target_3_SwissProt_ID:
P07477

# Drug_Target_3_SwissProt_Name:
TRY1_HUMAN

# Drug_Target_3_Synonyms:
Cationic trypsinogen
EC 3.4.21.4
Serine protease 1
Trypsin I
Trypsin-1 precursor

# Drug_Target_3_Theoretical_pI:
6.48

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Secreted protein
extracellular space

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
ABP1

# Drug_Target_4_GenBank_ID_Gene:
M55602

# Drug_Target_4_GenBank_ID_Protein:
177960

# Drug_Target_4_GeneCard_ID:
ABP1

# Drug_Target_4_Gene_Name:
ABP1

# Drug_Target_4_Gene_Sequence:
>2256 bp
ATGCCGGCCCTGGGCTGGGCCGTGGCTGCCATCCTGATGCTGCAGACGGCCATGGCGGAG
CCCTCCCCGGGGACTCTGCCCAGGAAGGCAGGGGTGTTTTCAGACCTAAGCAACCAAGAG
CTGAAGGCAGTGCACAGCTTCCTCTGGTCCAAGAAGGAGCTGAGGCTGCAGCCCTCCAGT
ACCACCACCATGGCCAAGAACACCGTGTTTCTCATCGAGATGCTGCTGCCCAAGAAGTAC
CATGTGCTGAGGTTTCTGGATAAAGGTGAAAGGCATCCTGTGCGGGAAGCCCGTGCCGTC
ATCTTCTTTGGTGACCAGGAGCATCCCAATGTCACCGAGTTTGCTGTGGGGCCCCTGCCA
GGGCCCTGCTACATGCGAGCACTGTCCCCCAGGCCTGGGTACCAGTCCTCCTGGGCATCG
AGGCCCATCTCCACAGCAGAGTATGCCCTCCTCTACCACACCCTGCAGGAAGCCACCAAG
CCCCTGCATCAGTTCTTCCTCAATACCACAGGCTTCTCATTCCAAGACTGCCATGACAGA
TGCCTGGCCTTCACCGATGTGGCCCCCCGGGGTGTGGCTTCTGGCCAGCGCCGCAGTTGG
CTTATCATACAGCGCTATGTAGAAGGCTACTTTCTGCACCCCACTGGGCTGGAGCTCCTC
GTGGATCATGGGAGCACAGATGCTGGGCACTGGGCCGTGGAGCAGGTGTGGTACAACGGG
AAGTTCTATGGGAGCCCAGAGGAACTGGCTCGGAAGTATGCAGATGGAGAGGTGGACGTG
GTGGTCCTGGAGGACCCGCTGCCTGGGGGCAAGGGGCATGACAGCACAGAGGAGCCGCCC
CTCTTCTCCTCCCACAAGCCCCGCGGGGACTTCCCCAGCCCCATCCATGTGAGCGGCCCC
CGCTTGGTCCAGCCCCACGGCCCTCGCTTCAGGCTGGAGGGCAACGCTGTGCTCTACGGC
GGCTGGAGCTTTGCCTTCCGGCTGCGCTCCTCCTCCGGGCTGCAGGTCCTGAACGTGCAC
TTCGGCGGAGAGCGCATTGCCTATGAGGTCAGCGTGCAAGAGGCAGTGGCGCTGTATGGA
GGACACACACCTGCAGGCATGCAGACCAAGTACCTCGATGTCGGCTGGGGCCTGGGCAGC
GTCACTCATGAGTTAGCCCCCGGCATCGACTGCCCGGAGACCGCCACCTTCCTGGACACT
TTCCACTACTATGATGCCGATGACCCGGTCCATTATCCCCGAGCCCTCTGCCTCTTTGAA
ATGCCCACAGGGGTGCCCCTTCGGCGGCACTTTAATTCCAACTTTAAAGGTGGCTTCAAC
TTCTATGCGGGGCTGAAGGGCCAGGTGCTGGTGCTGCGGACAACTTCAACTGTCTACAAT
TATGATTACATTTGGGACTTTATCTTCTACCCCAACGGGGTGATGGAGGCCAAGATGCAT
GCCACTGGCTACGTCCACGCCACCTTCTACACCCCCGAGGGGCTGCGCCACGGCACTCGC
CTGCACACCCACCTGATTGGCAACATACACACTCACTTGGTGCACTACCGCGTAGACCTG
GATGTGGCAGGCACCAAGAACAGCTTCCAGACACTGCAGATGAAGCTAGAAAACATCACC
AACCCCTGGAGCCCAAGACACCGCGTGGTCCAGCCAACTCTGGAGCAGACGCAGTACTCC
TGGGAGCGCCAGGCGGCCTTCCGCTTCAAAAGGAAGCTGCCCAAGTACCTGCTCTTTACC
AGCCCCCAGGAGAACCCCTGGGGCCACAAGCGCAGCTACCGCCTGCAGATCCACTCCATG
GCCGACCAGGTGCTGCCCCCAGGCTGGCAGGAGGAGCAGGCCATCACCTGGGCAAGGTAC
CCCCTGGCAGTGACCAAGTACCGGGAGTCGGAGCTGTGCAGCAGCAGCATCTACCACCAG
AACGACCCCTGGCACCCGCCCGTGGTCTTTGAGCAGTTTCTTCACAACAACGAGAACATT
GAAAATGAGGACCTGGTGGCCTGGGTGACGGTGGGCTTCCTGCACATCCCCCACTCAGAG
GACATTCCCAACACAGCCACACCTGGGAACTCCGTGGGCTTCCTGCTCCGGCCATTCAAC
TTCTTCCCAGAGGACCCCTCCCTGGCATCCAGAGACACTGTGATCGTGTGGCCTCGGGAC
AACGGCCCCAACTACGTCCAGCGCTGGATCCCTGAGGACAGGGACTGCTCGATGCCTCCC
CCTTTTAGCTACAATGGGACCTATAGACCTGTGTGA

# Drug_Target_4_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_4_General_References:
2217167	Barbry P, Champe M, Chassande O, Munemitsu S, Champigny G, Lingueglia E, Maes P, Frelin C, Tartar A, Ullrich A, et al.: Human kidney amiloride-binding protein: cDNA structure and functional expression. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7347-51.
8144586	Novotny WF, Chassande O, Baker M, Lazdunski M, Barbry P: Diamine oxidase is the amiloride-binding protein and is inhibited by amiloride analogues. J Biol Chem. 1994 Apr 1;269(13):9921-5.
8182053	Chassande O, Renard S, Barbry P, Lazdunski M: The human gene for diamine oxidase, an amiloride binding protein. Molecular cloning, sequencing, and characterization of the promoter. J Biol Chem. 1994 May 20;269(20):14484-9.
8595053	Zhang X, Kim J, McIntire WS: cDNA sequences of variant forms of human placenta diamine oxidase. Biochem Genet. 1995 Aug;33(7-8):261-8.

# Drug_Target_4_HGNC_ID:
HGNC:80

# Drug_Target_4_HPRD_ID:
00088

# Drug_Target_4_ID:
387

# Drug_Target_4_Locus:
7q34-q36

# Drug_Target_4_Molecular_Weight:
85342

# Drug_Target_4_Name:
Amiloride-sensitive amine oxidase [copper-containing]

# Drug_Target_4_Number_of_Residues:
751

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF01179	Cu_amine_oxid
PF02727	Cu_amine_oxidN2
PF02728	Cu_amine_oxidN3

# Drug_Target_4_Protein_Sequence:
>Amiloride-sensitive amine oxidase [copper-containing] precursor
MPALGWAVAAILMLQTAMAEPSPGTLPRKAGVFSDLSNQELKAVHSFLWSKKELRLQPSS
TTTMAKNTVFLIEMLLPKKYHVLRFLDKGERHPVREARAVIFFGDQEHPNVTEFAVGPLP
GPCYMRALSPRPGYQSSWASRPISTAEYALLYHTLQEATKPLHQFFLNTTGFSFQDCHDR
CLAFTDVAPRGVASGQRRSWLIIQRYVEGYFLHPTGLELLVDHGSTDAGHWAVEQVWYNG
KFYGSPEELARKYADGEVDVVVLEDPLPGGKGHDSTEEPPLFSSHKPRGDFPSPIHVSGP
RLVQPHGPRFRLEGNAVLYGGWSFAFRLRSSSGLQVLNVHFGGERIAYEVSVQEAVALYG
GHTPAGMQTKYLDVGWGLGSVTHELAPGIDCPETATFLDTFHYYDADDPVHYPRALCLFE
MPTGVPLRRHFNSNFKGGFNFYAGLKGQVLVLRTTSTVYNYDYIWDFIFYPNGVMEAKMH
ATGYVHATFYTPEGLRHGTRLHTHLIGNIHTHLVHYRVDLDVAGTKNSFQTLQMKLENIT
NPWSPRHRVVQPTLEQTQYSWERQAAFRFKRKLPKYLLFTSPQENPWGHKRSYRLQIHSM
ADQVLPPGWQEEQAITWARYPLAVTKYRESELCSSSIYHQNDPWDPPVVFEQFLHNNENI
ENEDLVAWVTVGFLHIPHSEDIPNTATPGNSVGFLLRPFNFFPEDPSLASRDTVIVWPRD
NGPNYVQRWIPEDRDCSMPPPFSYNGTYRPV

# Drug_Target_4_Reaction:
RCH2NH2 + H2O + O2 = RCHO + NH3 + H2O2

# Drug_Target_4_Signals:
1-19

# Drug_Target_4_Specific_Function:
Catalyzes the degradation of compounds such as putrescine, histamine, spermine, and spermidine, substances involved in allergic and immune responses, cell proliferation, tissue differentiation, tumor formation, and possibly apoptosis. Placental DAO is thought to play a role in the regulation of the female reproductive function

# Drug_Target_4_SwissProt_ID:
P19801

# Drug_Target_4_SwissProt_Name:
ABP1_HUMAN

# Drug_Target_4_Synonyms:
ABP
Amiloride-binding protein
Amiloride-sensitive amine oxidase precursor
DAO
Diamine oxidase
EC 1.4.3.6
Histaminase
KAO
Kidney amine oxidase

# Drug_Target_4_Theoretical_pI:
7.01

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB03608
